Global Aflibercept Biosimilars Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

The report published by Extent Research on global Aflibercept Biosimilars market has evaluated and researched the impact of the current COVID-19 pandemic on the industry. This report also covers the potential opportunity and challenges, drivers, and risks that will help the market expand over the forecast period. Furthermore, the market scenarios including market revenue, share, size, supply & demand analysis, and consumer preference help predict the impact of the pandemic on the Aflibercept Biosimilars industry. The research report on global Aflibercept Biosimilars market provides a detailed analysis of the market hindrances and drivers that have a huge impact on the overall market growth.

Data provided by Extent Research. Source: https://www.extentresearch.com/aflibercept-biosimilars-market

The impact of the latest trends and future prospects define the trajectories of the global Aflibercept Biosimilars market. The research report also covers the in-depth study of the achievements made by the key players in the Aflibercept Biosimilars industry. Some of the key players mentioned in the report include Regeneron, Sanofi, Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm, PharmaPraxis, Samsung Bioepis, Centus, Cadila Pharmaceuticals, Dr Reddy’s, Aurobindo Pharma, Biocad, MAbxience, Hetero, Biocon, Kirin Biologics, Mylan, BeiGene, Innovent, Qilu Pharmaceutical, Hengrui Pharmaceuticals, Hisun Pharmaceutical, TOT BIOPHARM, . Additionally, the lucrative trends in the market are also notified. Basically, the report aims to offer a holistic, unbiased, and comprehensive outlook of the market. For obtaining a better understanding of the Aflibercept Biosimilars market, the market is segmented based on application, end-users, product type, geography, and competitive players.

Moreover, the report accurately represents the market growth through the graphs, bar diagrams, tables, and other figurative representations. The breakdown structure of the market delivered in the report provides an objective view of the global Aflibercept Biosimilars market. The intricate and exhaustive details are anticipated to help make sound investments. Additionally, the regional development status offers a better understanding over the changing political scenario. Also, the impact of the political and socio-economic status of the regions on the market dynamics is also reported. The major regions including North America, Europe, Asia Pacific, Latin America, Middle East & Africa are the hub for the Aflibercept Biosimilars industry.

For collating this report, the research analysts have used primary and secondary research methodologies coupled with expert authentication. In conclusion, the development statuses, financial outlooks, key players, expansion trends, and strategic initiatives provide an overview of the Aflibercept Biosimilars market.

Segmentation of the Global Aflibercept Biosimilars Market:

By Product type

Intravitreal Injection, Intravenous Injection,

by Application

Wet Macular Degeneration, Metastatic Colorectal Cancer,

Report Scope and Market Segmentation

ATTRIBUTES	Global Aflibercept Biosimilars Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Aflibercept Biosimilars Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Aflibercept Biosimilars Market Overview
    1.1 Product Overview and Scope of Aflibercept Biosimilars
    1.2 Aflibercept Biosimilars Segment by Type
        1.2.1 Global Aflibercept Biosimilars Sales Growth Rate Comparison by Type (2022-2035)
        1.2.2 Intravitreal Injection
        1.2.3 Intravenous Injection
    1.3 Aflibercept Biosimilars Segment by Application
        1.3.1 Global Aflibercept Biosimilars Sales Comparison by Application: (2022-2035)
        1.3.2 Wet Macular Degeneration
        1.3.3 Metastatic Colorectal Cancer
    1.4 Global Aflibercept Biosimilars Market Size Estimates and Forecasts
        1.4.1 Global Aflibercept Biosimilars Revenue 2017-2035
        1.4.2 Global Aflibercept Biosimilars Sales 2017-2035
        1.4.3 Aflibercept Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2035
2 Aflibercept Biosimilars Market Competition by Manufacturers
    2.1 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Aflibercept Biosimilars Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Aflibercept Biosimilars Manufacturing Sites, Area Served, Product Type
    2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
        2.5.1 Aflibercept Biosimilars Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Aflibercept Biosimilars Players Market Share by Revenue
        2.5.3 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Aflibercept Biosimilars Retrospective Market Scenario by Region
    3.1 Global Aflibercept Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Aflibercept Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Aflibercept Biosimilars Market Facts & Figures by Country
        3.3.1 North America Aflibercept Biosimilars Sales by Country
        3.3.2 North America Aflibercept Biosimilars Revenue by Country
        3.3.3 United States
        3.3.4 Canada
    3.4 Europe Aflibercept Biosimilars Market Facts & Figures by Country
        3.4.1 Europe Aflibercept Biosimilars Sales by Country
        3.4.2 Europe Aflibercept Biosimilars Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Aflibercept Biosimilars Market Facts & Figures by Region
        3.5.1 Asia Pacific Aflibercept Biosimilars Sales by Region
        3.5.2 Asia Pacific Aflibercept Biosimilars Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Aflibercept Biosimilars Market Facts & Figures by Country
        3.6.1 Latin America Aflibercept Biosimilars Sales by Country
        3.6.2 Latin America Aflibercept Biosimilars Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Aflibercept Biosimilars Market Facts & Figures by Country
        3.7.1 Middle East and Africa Aflibercept Biosimilars Sales by Country
        3.7.2 Middle East and Africa Aflibercept Biosimilars Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Aflibercept Biosimilars Historic Market Analysis by Type
    4.1 Global Aflibercept Biosimilars Sales Market Share by Type (2017-2022)
    4.2 Global Aflibercept Biosimilars Revenue Market Share by Type (2017-2022)
    4.3 Global Aflibercept Biosimilars Price by Type (2017-2022)
5 Global Aflibercept Biosimilars Historic Market Analysis by Application
    5.1 Global Aflibercept Biosimilars Sales Market Share by Application (2017-2022)
    5.2 Global Aflibercept Biosimilars Revenue Market Share by Application (2017-2022)
    5.3 Global Aflibercept Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Regeneron
        6.1.1 Regeneron Corporation Information
        6.1.2 Regeneron Description and Business Overview
        6.1.3 Regeneron Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Regeneron Aflibercept Biosimilars Product Portfolio
        6.1.5 Regeneron Recent Developments/Updates
    6.2 Sanofi
        6.2.1 Sanofi Corporation Information
        6.2.2 Sanofi Description and Business Overview
        6.2.3 Sanofi Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Sanofi Aflibercept Biosimilars Product Portfolio
        6.2.5 Sanofi Recent Developments/Updates
    6.3 Novartis
        6.3.1 Novartis Corporation Information
        6.3.2 Novartis Description and Business Overview
        6.3.3 Novartis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Novartis Aflibercept Biosimilars Product Portfolio
        6.3.5 Novartis Recent Developments/Updates
    6.4 Genentech
        6.4.1 Genentech Corporation Information
        6.4.2 Genentech Description and Business Overview
        6.4.3 Genentech Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Genentech Aflibercept Biosimilars Product Portfolio
        6.4.5 Genentech Recent Developments/Updates
    6.5 Roche
        6.5.1 Roche Corporation Information
        6.5.2 Roche Description and Business Overview
        6.5.3 Roche Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Roche Aflibercept Biosimilars Product Portfolio
        6.5.5 Roche Recent Developments/Updates
    6.6 Pfizer
        6.6.1 Pfizer Corporation Information
        6.6.2 Pfizer Description and Business Overview
        6.6.3 Pfizer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Pfizer Aflibercept Biosimilars Product Portfolio
        6.6.5 Pfizer Recent Developments/Updates
    6.7 Sartorius
        6.6.1 Sartorius Corporation Information
        6.6.2 Sartorius Description and Business Overview
        6.6.3 Sartorius Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Sartorius Aflibercept Biosimilars Product Portfolio
        6.7.5 Sartorius Recent Developments/Updates
    6.8 Eli Lilly
        6.8.1 Eli Lilly Corporation Information
        6.8.2 Eli Lilly Description and Business Overview
        6.8.3 Eli Lilly Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Eli Lilly Aflibercept Biosimilars Product Portfolio
        6.8.5 Eli Lilly Recent Developments/Updates
    6.9 Bayer
        6.9.1 Bayer Corporation Information
        6.9.2 Bayer Description and Business Overview
        6.9.3 Bayer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Bayer Aflibercept Biosimilars Product Portfolio
        6.9.5 Bayer Recent Developments/Updates
    6.10 Amgen
        6.10.1 Amgen Corporation Information
        6.10.2 Amgen Description and Business Overview
        6.10.3 Amgen Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Amgen Aflibercept Biosimilars Product Portfolio
        6.10.5 Amgen Recent Developments/Updates
    6.11 PlantForm
        6.11.1 PlantForm Corporation Information
        6.11.2 PlantForm Aflibercept Biosimilars Description and Business Overview
        6.11.3 PlantForm Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 PlantForm Aflibercept Biosimilars Product Portfolio
        6.11.5 PlantForm Recent Developments/Updates
    6.12 PharmaPraxis
        6.12.1 PharmaPraxis Corporation Information
        6.12.2 PharmaPraxis Aflibercept Biosimilars Description and Business Overview
        6.12.3 PharmaPraxis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 PharmaPraxis Aflibercept Biosimilars Product Portfolio
        6.12.5 PharmaPraxis Recent Developments/Updates
    6.13 Samsung Bioepis
        6.13.1 Samsung Bioepis Corporation Information
        6.13.2 Samsung Bioepis Aflibercept Biosimilars Description and Business Overview
        6.13.3 Samsung Bioepis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
        6.13.5 Samsung Bioepis Recent Developments/Updates
    6.14 Centus
        6.14.1 Centus Corporation Information
        6.14.2 Centus Aflibercept Biosimilars Description and Business Overview
        6.14.3 Centus Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Centus Aflibercept Biosimilars Product Portfolio
        6.14.5 Centus Recent Developments/Updates
    6.15 Cadila Pharmaceuticals
        6.15.1 Cadila Pharmaceuticals Corporation Information
        6.15.2 Cadila Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
        6.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
        6.15.5 Cadila Pharmaceuticals Recent Developments/Updates
    6.16 Dr Reddy's
        6.16.1 Dr Reddy's Corporation Information
        6.16.2 Dr Reddy's Aflibercept Biosimilars Description and Business Overview
        6.16.3 Dr Reddy's Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.16.4 Dr Reddy's Aflibercept Biosimilars Product Portfolio
        6.16.5 Dr Reddy's Recent Developments/Updates
    6.17 Aurobindo Pharma
        6.17.1 Aurobindo Pharma Corporation Information
        6.17.2 Aurobindo Pharma Aflibercept Biosimilars Description and Business Overview
        6.17.3 Aurobindo Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.17.4 Aurobindo Pharma Aflibercept Biosimilars Product Portfolio
        6.17.5 Aurobindo Pharma Recent Developments/Updates
    6.18 Biocad
        6.18.1 Biocad Corporation Information
        6.18.2 Biocad Aflibercept Biosimilars Description and Business Overview
        6.18.3 Biocad Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.18.4 Biocad Aflibercept Biosimilars Product Portfolio
        6.18.5 Biocad Recent Developments/Updates
    6.19 MAbxience
        6.19.1 MAbxience Corporation Information
        6.19.2 MAbxience Aflibercept Biosimilars Description and Business Overview
        6.19.3 MAbxience Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.19.4 MAbxience Aflibercept Biosimilars Product Portfolio
        6.19.5 MAbxience Recent Developments/Updates
    6.20 Hetero
        6.20.1 Hetero Corporation Information
        6.20.2 Hetero Aflibercept Biosimilars Description and Business Overview
        6.20.3 Hetero Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.20.4 Hetero Aflibercept Biosimilars Product Portfolio
        6.20.5 Hetero Recent Developments/Updates
    6.21 Biocon
        6.21.1 Biocon Corporation Information
        6.21.2 Biocon Aflibercept Biosimilars Description and Business Overview
        6.21.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.21.4 Biocon Aflibercept Biosimilars Product Portfolio
        6.21.5 Biocon Recent Developments/Updates
    6.22 Kirin Biologics
        6.22.1 Kirin Biologics Corporation Information
        6.22.2 Kirin Biologics Aflibercept Biosimilars Description and Business Overview
        6.22.3 Kirin Biologics Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.22.4 Kirin Biologics Aflibercept Biosimilars Product Portfolio
        6.22.5 Kirin Biologics Recent Developments/Updates
    6.23 Mylan
        6.23.1 Mylan Corporation Information
        6.23.2 Mylan Aflibercept Biosimilars Description and Business Overview
        6.23.3 Mylan Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.23.4 Mylan Aflibercept Biosimilars Product Portfolio
        6.23.5 Mylan Recent Developments/Updates
    6.24 BeiGene
        6.24.1 BeiGene Corporation Information
        6.24.2 BeiGene Aflibercept Biosimilars Description and Business Overview
        6.24.3 BeiGene Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.24.4 BeiGene Aflibercept Biosimilars Product Portfolio
        6.24.5 BeiGene Recent Developments/Updates
    6.25 Innovent
        6.25.1 Innovent Corporation Information
        6.25.2 Innovent Aflibercept Biosimilars Description and Business Overview
        6.25.3 Innovent Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.25.4 Innovent Aflibercept Biosimilars Product Portfolio
        6.25.5 Innovent Recent Developments/Updates
    6.26 Qilu Pharmaceutical
        6.26.1 Qilu Pharmaceutical Corporation Information
        6.26.2 Qilu Pharmaceutical Aflibercept Biosimilars Description and Business Overview
        6.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
        6.26.5 Qilu Pharmaceutical Recent Developments/Updates
    6.27 Hengrui Pharmaceuticals
        6.27.1 Hengrui Pharmaceuticals Corporation Information
        6.27.2 Hengrui Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
        6.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Product Portfolio
        6.27.5 Hengrui Pharmaceuticals Recent Developments/Updates
    6.28 Hisun Pharmaceutical
        6.28.1 Hisun Pharmaceutical Corporation Information
        6.28.2 Hisun Pharmaceutical Aflibercept Biosimilars Description and Business Overview
        6.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Product Portfolio
        6.28.5 Hisun Pharmaceutical Recent Developments/Updates
    6.29 TOT BIOPHARM
        6.29.1 TOT BIOPHARM Corporation Information
        6.29.2 TOT BIOPHARM Aflibercept Biosimilars Description and Business Overview
        6.29.3 TOT BIOPHARM Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.29.4 TOT BIOPHARM Aflibercept Biosimilars Product Portfolio
        6.29.5 TOT BIOPHARM Recent Developments/Updates
7 Aflibercept Biosimilars Manufacturing Cost Analysis
    7.1 Aflibercept Biosimilars Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Aflibercept Biosimilars
    7.4 Aflibercept Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Aflibercept Biosimilars Distributors List
    8.3 Aflibercept Biosimilars Customers
9 Aflibercept Biosimilars Market Dynamics
    9.1 Aflibercept Biosimilars Industry Trends
    9.2 Aflibercept Biosimilars Market Drivers
    9.3 Aflibercept Biosimilars Market Challenges
    9.4 Aflibercept Biosimilars Market Restraints
10 Global Market Forecast
    10.1 Aflibercept Biosimilars Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Aflibercept Biosimilars by Type (2023-2035)
        10.1.2 Global Forecasted Revenue of Aflibercept Biosimilars by Type (2023-2035)
    10.2 Aflibercept Biosimilars Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Aflibercept Biosimilars by Application (2023-2035)
        10.2.2 Global Forecasted Revenue of Aflibercept Biosimilars by Application (2023-2035)
    10.3 Aflibercept Biosimilars Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Aflibercept Biosimilars by Region (2023-2035)
        10.3.2 Global Forecasted Revenue of Aflibercept Biosimilars by Region (2023-2035)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Aflibercept Biosimilars Market